A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences.
Eric D. Hsi(Mayo Clinic), Robert Coupland(Cancer Institute (WIA)), Brad Pohlman(Cleveland Clinic), Imran Mirza(Cancer Institute (WIA)), John W. Hill(Cleveland Clinic), Matthew Karafa(Cleveland Clinic), Gerard Lozanski(The Ohio State University)
Cited by 31
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Communication Skills Training for Physicians Improves Patient Satisfaction
|Journal of General Internal Medicine|2016|568